Your browser doesn't support javascript.
Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors.
Goto, Atsushi; Go, Hirofumi; Miyakawa, Kei; Yamaoka, Yutaro; Ohtake, Norihisa; Kubo, Sousuke; Jeremiah, Sundararaj Stanleyraj; Mihara, Takahiro; Senuki, Kotaro; Miyazaki, Tomoyuki; Ikeda, Satoshi; Ogura, Takashi; Kato, Hideaki; Matsuba, Ikuro; Sanno, Naoko; Miyakawa, Masaaki; Ozaki, Haruo; Kikuoka, Masakazu; Ohashi, Yasuo; Ryo, Akihide; Yamanaka, Takeharu.
  • Goto A; Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan.
  • Go H; Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Miyakawa K; Department of Microbiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Yamaoka Y; Department of Microbiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Ohtake N; Life Science Laboratory, Technology and Development Division, Kanto Chemical Co, Inc., Kanagawa, Japan.
  • Kubo S; Bioscience Division, Research and Development Department, Tosoh Corporation, Tokyo Research Center, Kanagawa, Japan.
  • Jeremiah SS; Advanced Medical Research Center, Yokohama City University, Yokohama, Japan.
  • Mihara T; Department of Microbiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Senuki K; Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Miyazaki T; Department of Microbiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Ikeda S; Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan.
  • Ogura T; YCU Center for Novel and Exploratory Clinical Trials, Yokohama City University Hospital, Yokohama, Japan.
  • Kato H; Department of Physiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Matsuba I; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
  • Sanno N; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
  • Miyakawa M; Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan.
  • Ozaki H; Matsuba Medical Clinic, Kanagawa, Japan.
  • Kikuoka M; Sanno Clinic Shinagawa, Tokyo, Japan.
  • Ohashi Y; Japan Medical Association, Tokyo, Japan.
  • Ryo A; Tokyo Medical Association, Tokyo, Japan.
  • Yamanaka T; Kanagawa Prefecture Medical Association, Yokohama, Japan.
Front Microbiol ; 12: 661187, 2021.
Article in English | MEDLINE | ID: covidwho-1241181
ABSTRACT

Objective:

There is scarce evidence regarding the long-term persistence of neutralizing antibodies among coronavirus disease 2019 (COVID-19) survivors. This study determined neutralizing antibody titers (NT50) and antibodies against spike protein (SP) or nucleocapsid protein (NP) antigens approximately 6 months after the diagnosis of COVID-19.

Methods:

COVID-19 survivors in Japan were recruited. Serum samples and data related to patients' characteristics and COVID-19 history were collected. NT50 and titers of antibodies against NP and SP antigens were measured at 20-32 weeks after the first positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results. Factors associated with NT50 were identified using the multivariable linear regression and the correlations among NT50 and titers of immunoglobulin G (IgG) and total immunoglobulins (Igs) against NP and SP were assessed by Spearman's correlation.

Results:

Among 376 participants (median [range] days after testing positive for SARS-CoV-2, 180 (147-224); median [range] years of age, 50 (20-78); 188 [50%] male), most tested positive for NT50 (n = 367, 98%), SP-IgG (n = 344, 91%), SP-total Ig (n = 369, 98%), NP-IgG (n = 314, 84%), and NP-total Ig (n = 365, 97%). Regression analysis indicated that higher BMI, fever, and the requirement of mechanical ventilation or extracorporeal membrane oxygenation were significantly associated with higher NT50. Anti-SP antibodies correlated moderately with NT50 (Spearman's correlation 0.63 for SP IgG; 0.57 for SP-total Ig), while the correlation was weak for anti-NP antibodies (0.37 for NP IgG; 0.32 for NP-total Ig).

Conclusions:

Most COVID-19 survivors had sustained neutralizing antibodies and tested positive for SP-total Ig and NP-total Ig approximately 6 months after infection.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Prognostic study Language: English Journal: Front Microbiol Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Prognostic study Language: English Journal: Front Microbiol Year: 2021
...